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Abstract
NK cells kill target cells mainly via exocytosis of granules containing perforin (perf) and granzymes (gzm). In vitro, gzm
delivery into the target cell cytosol results in apoptosis, and induction of apoptosis is severely impaired in the absence of
gzm A and B. However, their importance for in vivo cytotoxicity by cytotoxic T cells has been questioned. We used an in vivo
NK cytotoxicity assay, in which splenocytes from wild-type and b2microglobulin-deficient (MHC-I
neg) mice are co-injected
into recipients whose NK cells were activated by virus infection or synthetic Toll-like receptor ligands. Elimination of
adoptively transferred MHC-Ineg splenocytes was unimpaired in the absence of gzmA and gzmB, but dependent on perforin.
This target cell rejection was NK cell dependent, since NK cell depletion abrogated it. Furthermore, target cell elimination in
vivo was equally rapid in both wild-type and gzmAxB-deficient recipients, with the majority of specific target cells lost from
lymphoid tissue within less than one to two hours after transfer. Thus, similar to T cell cytotoxicity, the contribution of gzmA
and B to in vivo target cell elimination remains unresolved.
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Introduction
Gzm A and B are the most abundant and best characterized
members of the granzyme family, a family of proteinases residing
in the cytolytic granules of NK cells, cytotoxic T (Tc) cells and
other haemopoetic cells [1]. In vitro, gzmB induces target cell
death via caspase-dependent and –independent pathways, whereas
gzmA mediates its effect caspase-independently (reviewed in [2]),
although the cytotoxic potential of gzmA has recently been
questioned [3,4]. Most of what we know about granzyme function
originates from in vitro studies, using purified enzymes and their
delivery via perforin or other membrane-permeabilizing agents.
Notably, NK cells and Tc cells from mice deficient in gzmA or B,
or those defective in both gzmA and part of the gzmB cluster [5],
are still capable of inducing cell death in traditional cytotoxicity
assays, although their ability to induce nucleolysis and certain
apoptotic features in target cells is impaired or delayed [6]. More
recently, human NK cells were proposed to preferentially use
gzmB to kill their targets in vitro [7]. Our knowledge of gzm
function in vivo is limited. Despite the long-held assumption of
gzms as the main agents of cell death induction delivered by
perforin, there are relatively few in vivo models where gzmA and B
play a decisive role in recovery from pathogen infection or tumour
burden. Thus, mice deficient in gzmA, gzmB cluster, or both are
more susceptible to infection with herpesvirus, particularly
cytomegalovirus [8–10], and mousepox, ectromelia virus [11,12],
but their role in NK cell-mediated tumour rejection has been
controversial [13–15]. They appear, however, to play a role in NK
cell-mediated immunopathology [16]. Importantly, previous
studies on the role of gzm on NK cell-mediated tumor rejection
in vivo, measured long-term survival of the tumor after injection
into naı¨ve (or tumor-primed) mice, whereas the immediate
pathways by which gzmA and gzmB mediate their effect in these
models are still uncharacterised. Recent evidence suggest that
gzmA is not cytotoxic [3,4], but is a modulator of inflammation
[3]. We have previously described that, in contrast to in vitro
studies, gzmB and gzmA were not necessary for the in vivo
elimination of cognate, MHC-I-restricted Tc cell targets [17]. In
order to assess whether gzmA and/or gzmB are also dispensable in
vivo for NK cell cytolytic function, we have used an in vivo NK
cell assay targeting surface MHC-I deficient (MHC-Ineg) targets
[18]. We found that, as for cytotoxic T cells, activated NK cells
without gzmA or B are able to rapidly eliminate NK cell sensitive
target cells in vivo.
Results
Perforin-dependent elimination of MHC-Ineg lymphocytes
from virus-primed mice
In order to determine short-term in vivo cytotoxicity by
activated NK cells we used splenocytes from WT (MHC-Ipos)
and b2-microglobulin-deficient b2m
2/2; MHC-Ineg) mice as NK
cell-resistant and susceptible targets, respectively [18]. We used
infection with an avirulent strain of Semliki Forest virus (aSFV) to
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induce NK cells in vivo, because it a) induces a potent NK cell
response but no antiviral CD8 T cell response in C57Bl/6 mice
[16,19], and b) does not result in pathology in gzmAxB2/2 or
perf2/2 mice (data not shown). Splenic NK cell activity as a result
of aSFV infection peaks three days post-infection [20]. A mixture
of CFSE-labelled WT and b2m
2/2 splenocytes was injected i.v.
into virus-infected recipient mice that were deficient or not in
various components of the granule exocytosis pathway (gzmA+B
and perforin). At 3 and 14 hours after cell transfer, recipient
spleens were removed and the donor target cells (which were
detectable by virtue of their CFSE-mediated fluorescence)
enumerated by flow cytometry, and the specific elimination of
b2m
2/2 splenocytes (specific target cells) relative to WT
splenocytes (control cells) calculated, comparing the observed
ratio of the two cell populations in the recovered cell populations
and their ratio in the injected mixture. Three hours after transfer,
about half or more of the MHC-Ineg target cells had disappeared
from the spleens of WT and gzmAxB2/2 recipients, whereas in
perf2/2 recipients the ratio of MHCpos to MHC-Ineg targets was
virtually the same as that originally injected (Fig. 1A,B). By
14 hours post-transfer, MHC- target cell clearance had further
advanced in WT and gzmAxB2/2 recipients, and at this point
even infected perf2/2, as well as naı¨ve, recipients now also showed
significant, albeit much lower, specific target cell elimination.
Similar ratios, but much lower total numbers, of control to specific
targets were found in lymph nodes (data not shown). This target
cell elimination was not unique to SFV-infected mice, but also
found in mice that were infected with influenza virus (data not
shown) or mice treated 36 h previously with polyinosinic
polycytosinic acid (poly-(I:C)), a synthetic double-stranded RNA
analogue and Toll-like receptor 3 ligand that induces potent NK
cell cytotoxicity (Fig. 1E).
As reported by Ley and colleagues [8], most resting NK cells in
naı¨ve mice already expressed gzmA protein (88+/23% of splenic
NK cells and 55+/22% of popliteal lymph node NK cells) but few
expressed gzmB protein (,10% of NK cells in either spleen or
popliteal lymph nodes). Three days after infection with aSFV the
percentage of gzmA expressing NK cells had not changed
significantly (data not shown) whereas a large (.60%), similar
proportion of NK cells in gzm-sufficient animals were activated, as
assessed by intracellular gzmB protein expression of NK cells in
spleens (Fig. 1D) and popliteal lymph nodes (data not shown).
Furthermore, GKO mice contained similar proportions of NK1.1+
cells (Fig. 1C), as well as similar numbers of total splenocytes (data
not shown), both observations together suggesting similar
‘‘effector-to-target’’ ratios in vivo.
We were wondering whether gzmAxB2/2 mice might express
other – so-called orphan – granzymes that might compensate for
the loss of the supposedly principal cytotoxic gzmB, but this
appeared not to be the case. If anything, gzmAxB2/2 expressed
lower amounts of orphan gzm mRNA than WT and perf2/2 mice
(Table 1).
In vivo elimination of MHC-Ineg NK cell targets is
independent of gzmA and B
To assess the contribution, or lack thereof, of the two principal gzm
to the elimination of MHC-I- lymphocytes in vivo we tested single-
gzmGKO mice along with WT and perf2/2 mice, with similar
results: over 6 hours, virus-infected WT, gzmA2/2, gzmB2/2 and
gzmAxB2/2 mice all cleared MHC-Ineg lymphocytes with similar
efficiency, whereas perf2/2 mice were severely deficient in this
clearance, with the target cell ratios in virus-primed perf2/2
recipients resembling those found in naı¨ve WT recipients (Fig. 2).
All mice had similar proportions of NK1.1+ splenocytes (Fig. 2C). In
some experiments, perf2/2 mice had up to 1.5-fold greater numbers
of total NK1.1+ splenocytes, due to their larger overall spleen
cellularity at 8 weeks of age, compared with mice of the other strains
Figure 1. Perforin-dependent elimination of MHC-Ineg lympho-
cytes from virus-infected recipients. (A,B) Naı¨ve or 3-day aSFV-
infected B6, gzmAxB2/2 or perf2/2 mice injected i.v. with a mix of CFSElo
MHC-Ineg and CFSEhi MHC-Ipos splenocytes from naı¨ve donors. Three or
14 hours after transfer, recipient spleens were analysed for the ratios of
the two donor cell populations and specific elimination of MHC-Ineg
target cells calculated. (A) Representative histograms of the donor cell
ratios in the injected target mix, and in splenocyte populations recovered
from WT, gzmAxB2/2 and perf2/2 recipients. (B) Comparison between
specific b2m
2/2 target cell elimination in WT, gzmAxB2/2 and perf2/2
recipients at 3 and 14 h post-transfer. (C,D) proportions of NK1.1+
splenocytes and proportions of gzmB-expressing NK1.1+ splenocytes. (E)
Specific elimination of MHC-Ineg donor cells 6 hours after transfer into
mice injected 36 h previously with poly-(I:C). Data shown are means +/2
STD from 3–4 mice per group, and are representative of two (E) or three
(A–D) experiments. n.d. = not determined.
doi:10.1371/journal.pone.0023252.g001
NK Cells Kill In Vivo without gzmA and B
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(data not shown). However, this increased number of NK cells clearly
did not compensate for the absence of perforin.
NK cell depletion abolishes the elimination of MHC-Ineg
lymphocytes in virus-infected mice
Although O¨berg et al. already demonstrated in their studies that
rejection of b2m
2/2 lymphocytes in this adoptive transfer model
was mediated by NK cells, their assays were based on naı¨ve
recipients. To ascertain that this was also the case in mice with
virus-activated NK cells, we depleted NK cells in our virus-
infected recipients by in vivo administration of anti asialo-GM1
antibody and performed the aforementioned in vivo transfer
assays. Depletion of NK1.1+ cells resulted in a substantial loss of
the recipients’ ability to reject MHC-Ineg targets (Fig. 3),
demonstrating that in this model, too, target cell killing is
mediated by NK cells. CD8+ T cells were unaffected (data not
shown) although it is unlikely that they contributed to the observed
target cell clearance, since a) aSFV does not generate CD8 T cell
responses in C57BL/6 mice [16], and b) the recipients’ CD8+ cells
were only displaying a partially activated phenotype
(CD69+CD252, [21]).
GzmA- and gzmB-independent, rapid rejection of
MHC-I- targets in virus-infected mice
We have shown that virus-immune Tc cells do not require
gzmA and gzmB for very rapid in vivo target cell killing, with the
majority of targets eliminated by less than 45 minutes after
transfer [17]. We therefore assessed the kinetics of NK cell-
mediated rejection of MHC-I- lymphocytes in vivo. We found that
WT recipients cleared the majority of target cells by 90 minutes,
with significant killing already demonstrable 30 minutes after
transfer, and clearance reaching 75% of MHC-Ineg targets by less
than 6 hours (Fig. 4A–C). Importantly, gzmAxB2/2 displayed
identical kinetics of target cell clearance, suggesting that these
granzymes are not required for the rapid in vivo killing kinetics
observed in virus-infected mice. Although both virus-infected
perf2/2 as well as naı¨ve WT recipients showed significant target
elimination by 6 hours, the observed levels were similar only to
those observed after 30 minutes in infected WT recipients.
Although WT C57Bl/6 and gzmAxB2/2 mice have similar
organogenesis and lymphoid compartments [6], and similar
proportions and numbers of NK cells were found in both strains,
we further assessed whether there were differences in the
migration of adoptively transferred donor cells to the recipients
lymphoid organs. Although control target cell recovery varied in
efficiency between experiments, within individual experiments we
always found WT control donor target cells in similar proportions
and numbers in both spleens (Fig. 4D) and popliteal lymph nodes
Table 1. Expression of cytolytic effector protein genesa.
perf gzm
A B C D E F K M
WT +++ +++ +++ ++ 2 2 + ++ ++
gzmAxB2/2 +++ 2 2 + 2 2 2 ++ ++
perf2/2 2 +++ +++ ++ 2 2 + ++ ++
aNormalized to GAPDH gene expression (GAPDH = 1): 2, ,1025; + 1025–1023;
++, 1023–1021; +++, .1021.
doi:10.1371/journal.pone.0023252.t001
Figure 2. In vivo elimination of MHC-Ineg lymphocytes from
virus-infected recipients is independent of gzmA and gzmB.
Naı¨ve or 3-day aSFV-infected single or double GKO mice were injected
i.v. with a 4:1 mix of CFSEhi MHC-Ineg and CFSElo MHC-Ipos naı¨ve
splenocytes. Four hours after transfer, recipient spleens were analysed
for the ratios of the two donor cell populations and specific elimination
of MHC-Ineg target cells calculated. (A) Dot plot showing the gating of
donor cells in the recipient splenocyte population. (B) Representative
dot plots from infected WT , gzmA2/2, gzmB2/2, gzmAxB2/2, perf2/2,
and naı¨ve WT recipients. (C) Specific target cell elimination and
proportions of NK1.1+ cells in recipient spleens. The data shown are
means +/2 SD from 3 mice per group and are representative of two
experiments.
doi:10.1371/journal.pone.0023252.g002
Figure 3. In vivo elimination of MHC-Ineg lymphocytes is NK-
cell dependent. GzmAxB2/2 mice were infected with aSFV and
injected at days 2 and 3 with anti-asialo GM1 antibody. At day 3 post-
infection, CFSE-labelled target cells were also injected and target cell
elimination analysed after 4 hours as in Fig. 1. (A) Proportion of NK1.1+
cells in spleen and popliteal lymph nodes of recipient mice after
sacrifice. (B) Specific elimination of MHC-Ineg target cells in NK-depleted
or non-depleted mice. Data shown are means +/2 SD.
doi:10.1371/journal.pone.0023252.g003
NK Cells Kill In Vivo without gzmA and B
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(data not shown), suggesting that these features are also unaltered
by the genetic alterations in the GKO strain.
Discussion
We have used an assay measuring the NK cell-mediated
elimination of MHC-Ineg lymphocytes in vivo to test the
requirement for the two principal gzm of cytolytic lymphocytes,
gzmA and gzmB, in this process. We show that rapid elimination
of target cells occurs almost identically in virus-infected mice that
are sufficient or deficient of these gzm, further challenging the
previously held dogma that they are required for rapid and
efficient target cell killing. Although even naı¨ve recipients were
able to reject target cells, rapid kinetics of target cell rejection, with
the majority of targets eliminated by 90 minutes post-transfer,
required that the mice be either virus-infected or stimulated with
NK cell-inducing reagents. These results are remarkably similar to
our recent findings made in a system of MHC-I-restricted, cognate
antigen-specific target cell killing by antiviral Tc cells [17], thus
leading to similar implications for the importance of gzmA and
gzmB in both Tc cell-mediated and NK cell-mediated killing.
Given that NK cells in perf2/2 mice expressed gzmB at levels
similar to those in WT mice, but these mice were severely deficient
in rejection of MHC-Ineg targets, the gain of cytotoxic effector
function observed after infection-mediated activation of NK cells is
likely not due to the observed gain in gzmB protein expression
after activation, but more likely due to the concurrent gain in
perforin protein expression [8]. Injection of b2m
2/2 splenocytes
by itself did not result in upregulation of gzmB expression in NK
cells from naı¨ve mice (data not shown). However, it was possible
that the gzmAxB-independent but perf-dependent in vivo
cytotoxicity by NK cells reported here was mediated by granzymes
other than A and B, which might be expressed in gzmAxB2/2
mice as a compensatory mechanism. Such a redundancy has been
proposed as an explanation for the lack of clear-cut phenotypes
associated with single gzm KO mice [22,23]. However, we found
that only gzmC was expressed differentially, with higher
expression in WT and perf2/2 cells than in gzmAxB2/2 cells
(Table 1), a finding consistent with the ‘‘knock-down’’ effect
described for gzm genes downstream of gzmB in the gzmB2/2
strain [5], from which the gzmAxB2/2 mice were bred. An
increased gzmC expression was also observed in Tc cells from
virus-infected mice of that strain [17]. Thus, we did not observe
any differential gzm gene expression in gzmAxB2/2 NK cells that
might have compensated for the loss of the postulated cytotoxic
requirement for gzmA and gzmB. However, a difference in
orphan gzm protein expression cannot formally be excluded since,
as has been shown for gzmB, mRNA expression does not
necessarily correlate with protein expression [8]. It is also highly
unlikely that NK cytolytic function in the gzm deficient mouse
strain was mediated via the Fas pathway because if it were, one
would expect such Fas mediated redundancy also to be observed
in perf2/2 mice.
While our data question an important in vivo role for gzmA and
gzmB in the rejection of naive MHC-Ineg lymphocytes, there may
be other situations where target cell rejection in vivo by NK cells is
mediated by other pathways. Notably, Grundy et al demonstrated
that tumor cells locating to the lung after injection were rejected,
also with quite rapid kinetics, but via a perforin-independent
pathway [24]. Also, injection of YAC-1 and RMA-S cells, targets
traditionally used as NK cell targets in vitro, led to rapid, NK-
dependent elimination of these cells in the recipient lungs [25],
although the dependency of this process on perforin was not
established in that study. It therefore appears, just like for in vitro
apoptosis assays [26], that the nature of the target cell has a
profound influence on the cytotoxic pathways employed by
cytolytic lymphocytes. Arguably, one would expect transformed
tumor cells to express a range of NK cell activating signals,
whereas the only signal in b2m
2/2 is the loss of MHC-I. An
important caveat of the type of assay used here is that only a small
proportion of injected donor splenocytes are recovered from the
recipient spleens at any one time (typically less than 10%; [17] and
data not shown) and it is conceivable that a large proportion of
cells suffers an uncertain fate elsewhere in the receipient. However,
despite similar limitations, this technique has been found useful
and widely applied to investigate in vivo Tc cell cytotoxicity [27].
In order to broaden our target cell range in our investigations,
we also used mixtures of (MHC-Ipos) RMA and (MHC-Ineg) RMA-
S cells. However, these cells do not localize to the spleen after i.v.
injection, and both the proportion as well as absolute number of
NK cells in the putatively relevant compartments (lungs and
peritoneum, after i.v. or intraperitoneal target cell injection,
respectively) were substantially lower in gzmAxB2/2 than in WT
recipients, rendering analysis of the data difficult due to the
varying effector to target cell ratios. The observation of reduced
Figure 4. In vivo elimination of MHC-Ineg lymphocytes in WT
and gzmAxB2/2 is equally rapid. 3-day aSFV-infected or naive mice
of the shown genotype were injected with 1:5 mix of CFSElo MHC-Ineg
and CFSEhi MHC-Ipos naı¨ve donor splenocytes. (A) Dot plot showing the
gating of donor cells in the recipient splenocyte population. (B)
Representative histograms gated on donor cells in infected WT,
gzmAxB2/2, perf2/2 or naı¨ve WT mice after 30 minutes or 5.5 h. (C)
Specific elimination of MHC-Ineg donor cells at various time points. (D)
Tracking of total WT control donor cells in WT gzmAxB2/2 and perf2/2
recipients. Data shown are means +/2 SD from 3–4 mice per group and
are representative of three experiments.
doi:10.1371/journal.pone.0023252.g004
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NK cell migration in the absence of gzm is consistent with the
notion that these enzymes have a role in lymphocyte homing and
migration ([28,29], and Murphy et al., manuscript in publication).
In both these models, however, the magnitude of target cell
rejection correlated well with local NK cell presence and perf-WT
genotype, but not with gzm expression (data not shown).
In conclusion, we show that, as for target cell elimination by
MHC-I-restricted Tc cells, rapid elimination of MHC-Ineg
lymphocytes by NK cells in vivo is perforin-dependent while
requiring neither gzmA nor gzmB. Together with our observations
for Tc cell-mediated in vivo cytotoxicity, [17], these findings add
weight to the notion that at least murine gzmA may not be
cytotoxic, while the cytotoxic potential of gzmB is still maintained
by others [3,4]. Further research into their in vivo function are
required to elucidate whether either gzm performs hitherto
unknown functions.
Materials and Methods
Mice and virus
Female C57BL/6 and gene-KO mice were obtained, at 6–8
weeks of age, from the specific pathogen-free facility at the John
Curtin School of Medical Research, and used according to
protocols approved by the Animal Experimentation Ethics
Committee (J.IG.68.08, J.IG.51.06, J.IG.19.03). GzmAxB2/2 mice
were originally generated by crossing the gzmA2/2 [22] and
gzmB2/2 [30] mice also used in this study. Perf2/2 mice were
originally generated by Ka¨gi et al. [31]. aSFV [20] and influenza A/
PR8 viruses [32] were grown and assayed as described previously.
Genotype of mice used in experiments was confirmed by PCR.
In vivo killing assays
For in vivo NK cell assays mice were infected i.v. with 107 PFU
aSFV, or 103 haemagglutination forming units influenza A/PR8,
or injected i.p. with 100 mg poly-(I:C). Three days after virus
infection or 36 h after poly-(I:C) injection, mice received 26107
cells of a mixture of CFSE labelled control WT or b2m
2/2
splenocytes i.v.. The cell ratios and CFSE concentrations used
varied between experiments. Typically, a ,4:1 ratio of cognate to
control cells were used in order to better follow the loss of cognate
target cells, but results were similar when equal ratios were used.
CFSE concentrations were 200–400 nM and 4–5 mM for the
CFSElo and CFSEhi target cells, respectively. At the indicated time
points after transfer, recipient spleens and popliteal lymph nodes
were harvested and donor target cells enumerated by FACS based
on their CFSE profiles.
Flow cytometry
Red-blood cell-lysed splenocytes, lung, lymph node and
peritoneal exudate cells were incubated in 7-aminoactinomycin
D and stained with antibodies against NK1.1 (both Pharmingen).
Cells were then fixed in 2% fresh paraformaldehyde, permeabi-
lized with 0.5% saponin and stained with polyclonal rabbit anti-
gzmA or anti-gzmB antiserum, followed by Alexa647-conjugated
rat anti-rabbit IgG (Molecular Probes). Cells were then analysed
on a FACSCalibur (Becton Dickinson). % Specific target cell loss
was calculated as % SL = 100–100/(number of recovered control
cells)*(number of recovered specific target cells)*(ratio control:
specific target cells in injected mix).
Analysis of perf and gzm gene expression
Total mRNA was isolated from 56105 NK1.1+ cells, positively
enriched by autoMACS (Miltenyi, Germany; according to the
manufacturer’s protocol), reverse-transcribed and assayed with
TaqMan Gene Expression assays (Applied Biosystems) on a
7900HT Fast real-time PCR system (Applied Biosystems, at the
ACRF Biomolecular Resource Facility, JCSMR). The copy
number obtained for each gene of interest was normalized to
the copy number of GAPDH mRNA ( = 1).
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